Biotechnology is one the strangest ... This is generally done through a series of at least three clinical trials. If these trials meet their goals of safety and efficacy (and these goals are ...

Adcendo, a developer of antibody-drug conjugates backed by TCGX, Orbimed and nearly a dozen other investors, raised a $135 ...

Enveda, a company using artificial intelligence to boost nature-based drug discovery, is envisioning clinical success with a ...

At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

BOSS began in 2010 as a partnership with the CU Biotech Club and the Deming Center for Entrepreneurship. Since then, BOSS has sponsored 21 seminars featuring industry leaders. BOSS has hosted John ...

The B-cell therapy company closed earlier this year after a lead investor backed out of a series B round. At the time, CEO Rusty Williams, M.D., Ph.D., told Fierce Biotech that the company was ...

an innovative biotech company developing the next generation of gene therapies, today announced the successful completion of a Series A financing of $20 million. Proceeds from the financing will ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...